{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:28:52Z","timestamp":1765232932371,"version":"3.37.3"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose of Review<\/jats:title>\n<jats:p>Stroke remains a devastating complication of cardiovascular interventions. This review is going to discuss stroke rates and outcomes in different cardiovascular procedures with a highlight on the current evidence for the use of cerebral protection devices (CPD).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Recent Findings<\/jats:title>\n<jats:p>Depending on the quality of neurological assessment, stroke occurs in up to 9.1% after TAVI, 3.9% after mitral clipping, 3.1% in LAAO patients, 0.4% after PCIs, and 1.8% after catheter ablation. CPDs are available for routine use. They are easy to use in most anatomies, feasible, and safe. Data on clinical impact and stroke reduction from RCTs are still missing.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Summary<\/jats:title>\n<jats:p>Most evidence for the routine use of CPDs exists in TAVI patients, who are at the highest risk. The PROTECTED TAVI RCT will shed more light on the clinical impact of CPD-use in TAVI patients. In other cardiovascular procedures like mitral clipping, PCIs, and ablation, the current data do not support the routine use of CPDs in these patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11886-020-01335-9","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T09:03:43Z","timestamp":1594371823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cerebral Protection Devices during Transcatheter Interventions: Indications, Benefits, and Limitations"],"prefix":"10.1007","volume":"22","author":[{"given":"Stephan","family":"Haussig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Linke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman","family":"Mangner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"key":"1335_CR1","doi-asserted-by":"crossref","first-page":"e010920","DOI":"10.1161\/JAHA.118.010920","volume":"8","author":"B Indja","year":"2019","unstructured":"Indja B, Woldendorp K, Vallely MP, Grieve SM. Silent brain infarcts following cardiac procedures: a systematic review and meta-analysis. J Am Heart Assoc. 2019;8:e010920.","journal-title":"J Am Heart Assoc"},{"key":"1335_CR2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jacc.2016.11.045","volume":"69","author":"AJ Lansky","year":"2017","unstructured":"Lansky AJ, Mess\u00e9 SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, et al. Proposed standardized neurological endpoints for cardiovascular clinical trials: an academic research consortium initiative. J Am Coll Cardiol. 2017;69:679\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jacc.2016.10.023","volume":"69","author":"SR Kapadia","year":"2017","unstructured":"\u2022 Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol. 2017;69:367\u201377. This is a randomized controlled trial showing a safe use of the Sentinel CPD, capturing embolic debris in 99% of the TAVI patients.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2017.06.045","volume":"70","author":"E Grube","year":"2017","unstructured":"Grube E, van Mieghem NM, Manoharan G, et al. Clinical outcomes with a repositionable self-expanding transcatheter aortic valve prosthesis: the International FORWARD study. J Am Coll Cardiol. 2017;70:845\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","volume":"380","author":"MJ Mack","year":"2019","unstructured":"Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695\u2013705.","journal-title":"N Engl J Med"},{"key":"1335_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jacc.2016.05.065","volume":"68","author":"V Auffret","year":"2016","unstructured":"Auffret V, Regueiro A, Trigo MD, Altisent OAJ, Campelo-Parada F, Chiche O, et al. Predictors of early cerebrovascular events in patients with aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;68:673\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR7","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","volume":"60","author":"AP Kappetein","year":"2012","unstructured":"Kappetein AP, Head SJ, G\u00e9n\u00e9reux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/eurheartj\/ehy847","volume":"40","author":"J Seeger","year":"2018","unstructured":"\u2022 Seeger J, Kapadia SR, Kodali S, Linke A, W\u00f6hrle J, Haussig S, et al. Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. Eur Heart J. 2018;40:1334\u201340. This study shows a 65% lower stroke rate within the first 72 hours after TAVI with the use of the Sentinel CPD compared to unprotected TAVI.","journal-title":"Eur Heart J"},{"key":"1335_CR9","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307\u201318.","journal-title":"N Engl J Med"},{"key":"1335_CR10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"J-F Obadia","year":"2018","unstructured":"Obadia J-F, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379:2297\u2013306.","journal-title":"N Engl J Med"},{"key":"1335_CR11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.4244\/EIJ-D-19-00602","volume":"15","author":"PB da Silva","year":"2020","unstructured":"\u2022 da Silva PB, Sousa JP, Oliveiros B, Donato H, Costa M, Gon\u00e7alves L, et al. Stroke after transcatheter edge-to-edge mitral valve repair: a systematic review and meta-analysis. EuroIntervention. 2020;15:1401\u20138. This is a large analysis of stroke rate in 1881 patients undergoing transcatheter or surgical mitral valve repair.","journal-title":"EuroIntervention"},{"key":"1335_CR12","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.4244\/EIJY14M05_10","volume":"10","author":"S Blazek","year":"2015","unstructured":"Blazek S, Lurz P, Mangner N, Fuernau G, Seeburger J, Luecke C, et al. Incidence, characteristics and functional implications of cerebral embolic lesions after the MitraClip procedure. EuroIntervention. 2015;10:1195\u2013203.","journal-title":"EuroIntervention"},{"key":"1335_CR13","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.jcin.2016.07.005","volume":"9","author":"G Nickenig","year":"2016","unstructured":"Nickenig G, Hammerstingl C, Schueler R, Topilsky Y, Grayburn PA, Vahanian A, et al. Transcatheter mitral annuloplasty in chronic functional mitral regurgitation: 6-month results with the cardioband percutaneous mitral repair system. JACC Cardiovasc Interv. 2016;9:2039\u201347.","journal-title":"JACC Cardiovasc Interv"},{"key":"1335_CR14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/eurheartj\/ehy424","volume":"40","author":"D Messika-Zeitoun","year":"2019","unstructured":"Messika-Zeitoun D, Nickenig G, Latib A, Kuck KH, Baldus S, Schueler R, et al. Transcatheter mitral valve repair for functional mitral regurgitation using the cardioband system: 1 year outcomes. Eur Heart J. 2019;40:466\u201372.","journal-title":"Eur Heart J"},{"key":"1335_CR15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","volume":"374","author":"DR Holmes","year":"2009","unstructured":"Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534\u201342.","journal-title":"Lancet"},{"key":"1335_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","volume":"64","author":"DR Holmes","year":"2014","unstructured":"Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR17","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4244\/EIJ-D-19-00507","volume":"15","author":"C Godino","year":"2020","unstructured":"Godino C, Melillo F, Bellini B, Mazzucca M, Pivato CA, Rubino F, et al. Percutaneous left atrial appendage closure versus non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation and high bleeding risk. EuroIntervention. 2020;15:1548\u201354.","journal-title":"EuroIntervention"},{"key":"1335_CR18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2019.12.040","volume":"75","author":"JV Freeman","year":"2020","unstructured":"Freeman JV, Varosy P, Price MJ, Price MJ, Slotwiner D, Kusumoto FM, et al. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol. 2020;75:1503\u201318.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4244\/EIJ-D-16-00776","volume":"13","author":"N Majunke","year":"2017","unstructured":"Majunke N, Eplinius F, Gutberlet M, Moebius-Winkler S, Daehnert I, Grothoff M, et al. Frequency and clinical course of cerebral embolism in patients undergoing transcatheter left atrial appendage closure. EuroIntervention. 2017;13:124\u201330.","journal-title":"EuroIntervention"},{"key":"1335_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.hrthm.2017.11.015","volume":"15","author":"A Rillig","year":"2018","unstructured":"Rillig A, Bellmann B, Skurk C, Leistner DM, Haeusler KG, Lin T, et al. Left atrial appendage angiography is associated with the incidence and number of magnetic resonance imaging-detected brain lesions after percutaneous catheter-based left atrial appendage closure. Heart Rhythm. 2018;15:3\u20138.","journal-title":"Heart Rhythm"},{"key":"1335_CR21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/ene.13129","volume":"24","author":"M Laible","year":"2017","unstructured":"Laible M, M\u00f6hlenbruch M, Horstmann S, Pfaff J, Geis NA, Pleger S, et al. Peri-procedural silent cerebral infarcts after left atrial appendage occlusion. Eur J Neurol. 2017;24:53\u20137.","journal-title":"Eur J Neurol"},{"key":"1335_CR22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2018.04.071","volume":"72","author":"SJ Head","year":"2018","unstructured":"Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Stroke rates following surgical versus percutaneous coronary revascularization. J Am Coll Cardiol. 2018;72:386\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"1335_CR23","doi-asserted-by":"publisher","unstructured":"Whitehead N, Williams T, Brienesse S, Ferreira D, Murray N, Inder K, et al. Contemporary trends in stroke complicating cardiac catheterization. Intern Med J. 2019. https:\/\/doi.org\/10.1111\/imj.14405.","DOI":"10.1111\/imj.14405"},{"key":"1335_CR24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ahj.2011.07.021","volume":"162","author":"N Schwarz","year":"2011","unstructured":"Schwarz N, Schoenburg M, M\u00f6llmann H, Kastaun S, Kaps M, Bachmann G, et al. Cognitive decline and ischemic microlesions after coronary catheterization. A comparison to coronary artery bypass grafting. Am Heart J. 2011;162:756\u201363.","journal-title":"Am Heart J"},{"key":"1335_CR25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1253\/circj.72.51","volume":"72","author":"M Murai","year":"2008","unstructured":"Murai M, Hazui H, Sugie A, Hoshiga M, Negoro N, Muraoka H, et al. Asymptomatic acute ischemic stroke after primary percutaneous coronary intervention in patients with acute coronary syndrome might be caused mainly by manipulating catheters or devices in the ascending aorta, regardless of the approach to the coronary artery. Circ J. 2008;72:51\u20135.","journal-title":"Circ J"},{"key":"1335_CR26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(09)61755-4","volume":"375","author":"K-H Kuck","year":"2010","unstructured":"Kuck K-H, Schaumann A, Eckardt L, Willems S, Ventura R, Delacr\u00e9taz E, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375:31\u201340.","journal-title":"Lancet"},{"key":"1335_CR27","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.hrthm.2011.05.017","volume":"8","author":"M Bohnen","year":"2011","unstructured":"Bohnen M, Stevenson WG, Tedrow UB, Michaud GF, John RM, Epstein LM, et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm. 2011;8:1661\u20136.","journal-title":"Heart Rhythm"},{"key":"1335_CR28","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCULATIONAHA.116.025546","volume":"135","author":"IR Whitman","year":"2017","unstructured":"Whitman IR, Gladstone RA, Badhwar N, Hsia HH, Lee BK, Josephson SA, et al. Brain emboli after left ventricular endocardial ablation. Circulation. 2017;135:867\u201377.","journal-title":"Circulation"},{"key":"1335_CR29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1540-8167.2009.01650.x","volume":"21","author":"D Patel","year":"2010","unstructured":"Patel D, Bailey SM, Furlan AJ, et al. Long-term functional and neurocognitive recovery in patients who had an acute cerebrovascular event secondary to catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21:412\u20137.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1335_CR30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCEP.109.859116","volume":"3","author":"R Cappato","year":"2010","unstructured":"Cappato R, Calkins H, Chen S-A, Davies W, Iesaka Y, Kalman J, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32\u20138.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"1335_CR31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hrthm.2009.07.007","volume":"6","author":"AA Hussein","year":"2009","unstructured":"Hussein AA, Martin DO, Saliba W, Patel D, Karim S, Batal O, et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm. 2009;6:1425\u20139.","journal-title":"Heart Rhythm"},{"key":"1335_CR32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1540-8167.2012.02420.x","volume":"24","author":"KG Haeusler","year":"2013","unstructured":"Haeusler KG, Koch L, Herm J, Kopp UA, Heuschmann PU, Endres M, et al. 3 tesla MRI-detected brain lesions after pulmonary vein isolation for atrial fibrillation: results of the MACPAF study. J Cardiovasc Electrophysiol. 2013;24:14\u201321.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1335_CR33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.amjcard.2016.07.011","volume":"118","author":"A Muralidharan","year":"2016","unstructured":"Muralidharan A, Thiagarajan K, Ham RV, Gleason TG, Mulukutla S, Schindler JT, et al. Meta-analysis of perioperative stroke and mortality in transcatheter aortic valve implantation. Am J Cardiol. 2016;118:1031\u201345.","journal-title":"Am J Cardiol"},{"key":"1335_CR34","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/01.STR.0000019289.15440.F2","volume":"33","author":"S-M Lai","year":"2002","unstructured":"Lai S-M, Studenski S, Duncan PW, Perera S. Persisting consequences of stroke measured by the stroke impact scale. Stroke. 2002;33:1840\u20134.","journal-title":"Stroke"},{"key":"1335_CR35","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1161\/STROKEAHA.108.534487","volume":"40","author":"K Daniel","year":"2009","unstructured":"Daniel K, Wolfe CDA, Busch MA, McKevitt C. What are the social consequences of stroke for working-aged adults? A systematic review. Stroke. 2009;40:e431\u201340.","journal-title":"Stroke"},{"key":"1335_CR36","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5271\/sjweh.3508","volume":"41","author":"J Gunn","year":"2015","unstructured":"Gunn J, Kiviniemi T, Biancari F, Kajander O, M\u00c3\u00a4kikallio T, Eskola M, et al. Predictors of permanent work disability among \u2264\u200950-year-old patients undergoing percutaneous coronary intervention. Scand J Work Environ Health. 2015;41:460\u20136.","journal-title":"Scand J Work Environ Health"},{"key":"1335_CR37","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1212\/WNL.57.7.1222","volume":"57","author":"C Bernick","year":"2001","unstructured":"Bernick C, Kuller L, Dulberg C, Longstreth WT, Manolio T, Beauchamp N, et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology. 2001;57:1222\u20139.","journal-title":"Neurology"},{"key":"1335_CR38","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.STR.0000068408.82115.D2","volume":"34","author":"SE Vermeer","year":"2003","unstructured":"Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, MMB B, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34:1126\u20139.","journal-title":"Stroke"},{"key":"1335_CR39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa022066","volume":"348","author":"SE Vermeer","year":"2003","unstructured":"Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215\u201322.","journal-title":"N Engl J Med"},{"key":"1335_CR40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijcard.2016.06.143","volume":"221","author":"M Pagnesi","year":"2016","unstructured":"Pagnesi M, Martino EA, Chiarito M, Mangieri A, Jabbour RJ, van Mieghem NM, et al. Silent cerebral injury after transcatheter aortic valve implantation and the preventive role of embolic protection devices: a systematic review and meta-analysis. Int J Cardiol. 2016;221:97\u2013106.","journal-title":"Int J Cardiol"},{"key":"1335_CR41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2014.7692","volume":"312","author":"S Koton","year":"2014","unstructured":"Koton S, Schneider ALC, Rosamond WD, Shahar E, Sang Y, Gottesman RF, et al. Stroke incidence and mortality trends in U.S. communities, 1987 to 2011. JAMA. 2014;312:259\u201368.","journal-title":"JAMA"},{"key":"1335_CR42","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1161\/STROKEAHA.110.602615","volume":"42","author":"KM Mohan","year":"2011","unstructured":"Mohan KM, Wolfe CDA, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42:1489\u201394.","journal-title":"Stroke"},{"key":"1335_CR43","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1161\/CIRCULATIONAHA.112.110981","volume":"126","author":"L Nombela-Franco","year":"2012","unstructured":"Nombela-Franco L, Webb JG, de Jaegere PP, Toggweiler S, Nuis RJ, Dager AE, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation. 2012;126:3041\u201353.","journal-title":"Circulation"},{"key":"1335_CR44","doi-asserted-by":"crossref","first-page":"e007546","DOI":"10.1161\/CIRCINTERVENTIONS.118.007546","volume":"12","author":"W Vlastra","year":"2019","unstructured":"Vlastra W, Quevedo PJ, Tchetche D, et al. Predictors, incidence, and outcomes of patients undergoing transfemoral transcatheter aortic valve implantation complicated by stroke. Circ Cardiovasc Interv. 2019;12:e007546.","journal-title":"Circ Cardiovasc Interv"},{"key":"1335_CR45","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jtcvs.2012.01.055","volume":"143","author":"DC Miller","year":"2012","unstructured":"Miller DC, Blackstone EH, Mack MJ, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg. 2012;143:832\u2013843.e13.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1335_CR46","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ccd.28391","volume":"95","author":"A Eitan","year":"2020","unstructured":"\u2022 Eitan A, Brinkmann C, Haselbach T, Witt J, Schofer J. Does valve in valve TAVR carry a higher risk for thromboembolic events compared to native valve TAVR? Catheter Cardiovasc Interv. 2020;95:1017\u201321. This recent study shows a lower incidence and number of new CELs in VIV procedures compared to TAVI in native valves.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1335_CR47","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ccd.27323","volume":"91","author":"L van Gils","year":"2018","unstructured":"van Gils L, Kroon H, Daemen J, Ren C, Maugenest A-M, Schipper M, et al. Complete filter-based cerebral embolic protection with transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 2018;91:790\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1335_CR48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jama.2016.10302","volume":"316","author":"S Haussig","year":"2016","unstructured":"Haussig S, Mangner N, Dwyer MG, Lehmkuhl L, L\u00fccke C, Woitek F, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA. 2016;316:592\u2013601.","journal-title":"JAMA"},{"key":"1335_CR49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ahj.2017.06.007","volume":"192","author":"T Rogers","year":"2017","unstructured":"Rogers T, Alraies MC, Torguson R, Waksman R. Overview of the 2017 U.S. Food and Drug Administration circulatory system devices panel meeting on the Sentinel cerebral protection system. Am Heart J. 2017;192:113\u20139.","journal-title":"Am Heart J"},{"key":"1335_CR50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.carrev.2019.11.014","volume":"21","author":"BC Case","year":"2020","unstructured":"Case BC, Forrestal BJ, Yerasi C, Khan JM, Khalid N, Shlofmitz E, et al. Real-world experience of the Sentinel cerebral protection device: insights from the FDA manufacturer and user facility device experience (MAUDE) database. Cardiovasc Revasc Med. 2020;21:235\u20138.","journal-title":"Cardiovasc Revasc Med"},{"key":"1335_CR51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/joic.12573","volume":"31","author":"T Gasior","year":"2018","unstructured":"Gasior T, Mangner N, Bijoch J, Wojakowski W. Cerebral embolic protection systems for transcatheter aortic valve replacement. J Interv Cardiol. 2018;31:891\u20138.","journal-title":"J Interv Cardiol"},{"key":"1335_CR52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4244\/EIJY15M04_01","volume":"11","author":"A Baumbach","year":"2015","unstructured":"Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, et al. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention. 2015;11:75\u201384.","journal-title":"EuroIntervention"},{"key":"1335_CR53","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/eurheartj\/ehv191","volume":"36","author":"AJ Lansky","year":"2015","unstructured":"Lansky AJ, Schofer J, Tchetche D, Stella P, Pietras CG, Parise H, et al. A prospective randomized evaluation of the TriGuard\u2122 HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J. 2015;36:2070\u20138.","journal-title":"Eur Heart J"},{"key":"1335_CR54","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.amjcard.2016.08.013","volume":"118","author":"AJ Lansky","year":"2016","unstructured":"Lansky AJ, Brown D, Pena C, Pietras CG, Parise H, Ng VG, et al. Neurologic complications of unprotected transcatheter aortic valve implantation (from the Neuro-TAVI trial). Am J Cardiol. 2016;118:1519\u201326.","journal-title":"Am J Cardiol"},{"key":"1335_CR55","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jcin.2019.11.017","volume":"13","author":"A Latib","year":"2020","unstructured":"\u2022 Latib A, Mangieri A, Vezzulli P, et al. First-in-man study evaluating the emblok embolic protection system during transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2020;13:860\u20138. This first-in-man study shows the safe use of a CPD with full vessel coverage.","journal-title":"JACC Cardiovasc Interv"},{"key":"1335_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15171\/jrip.2016.01","volume":"5","author":"W Cheungpasitporn","year":"2016","unstructured":"Cheungpasitporn W, Thongprayoon C, Kashani K. Transcatheter aortic valve replacement: a kidney\u2019s perspective. J Renal Inj Prev. 2016;5:1\u20137.","journal-title":"J Renal Inj Prev"},{"key":"1335_CR57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4244\/EIJV8I1A8","volume":"8","author":"CK Naber","year":"2012","unstructured":"Naber CK, Ghanem A, Abizaid AA, Wolf A, Sinning J-M, Werner N, et al. First-in-man use of a novel embolic protection device for patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2012;8:43\u201350.","journal-title":"EuroIntervention"},{"key":"1335_CR58","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/CIRCULATIONAHA.112.001091","volume":"127","author":"NM van Mieghem","year":"2013","unstructured":"van Mieghem NM, Schipper MEI, Ladich E, Faqiri E, van der Boon R, Randjgari A, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation. 2013;127:2194\u2013201.","journal-title":"Circulation"},{"key":"1335_CR59","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jcin.2015.01.020","volume":"8","author":"NM van Mieghem","year":"2015","unstructured":"van Mieghem NM, Faquir NE, Rahhab Z, et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015;8:718\u201324.","journal-title":"JACC Cardiovasc Interv"},{"key":"1335_CR60","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4244\/EIJV12I4A84","volume":"12","author":"NM van Mieghem","year":"2016","unstructured":"van Mieghem NM, van Gils L, Ahmad H, van Kesteren F, van der Werf HW, Brueren G, et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. EuroIntervention. 2016;12:499\u2013507.","journal-title":"EuroIntervention"},{"key":"1335_CR61","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jcin.2014.04.018","volume":"7","author":"D Tchetche","year":"2014","unstructured":"Tchetche D, Farah B, Misuraca L, Pierri A, Vahdat O, Lereun C, et al. Cerebrovascular events post-transcatheter aortic valve replacement in a large cohort of patients: a FRANCE-2 registry substudy. JACC Cardiovasc Interv. 2014;7:1138\u201345.","journal-title":"JACC Cardiovasc Interv"},{"key":"1335_CR62","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/eurheartj\/ehy880","volume":"40","author":"M Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab M, Thiele H. Cerebral embolic protection during TAVI: prevent the unpreventable? Eur Heart J. 2019;40:1340\u20131.","journal-title":"Eur Heart J"},{"key":"1335_CR63","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/jnnp.2008.169805","volume":"80","author":"JM Hong","year":"2009","unstructured":"Hong JM, Chung C-S, Bang OY, Yong SW, Joo IS, Huh K. Vertebral artery dominance contributes to basilar artery curvature and peri-vertebrobasilar junctional infarcts. J Neurol Neurosurg Psychiatry. 2009;80:1087\u201392.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1335_CR64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcin.2015.09.039","volume":"9","author":"C Frerker","year":"2016","unstructured":"Frerker C, Schl\u00fcter M, Sanchez OD, Reith S, Romero ME, Ladich E, et al. Cerebral protection during MitraClip implantation: initial experience at 2 centers. JACC Cardiovasc Interv. 2016;9:171\u20139.","journal-title":"JACC Cardiovasc Interv"},{"key":"1335_CR65","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.4244\/EIJ-D-17-00777","volume":"13","author":"G Tarantini","year":"2018","unstructured":"Tarantini G, D\u2019Amico G, Latib A, et al. Percutaneous left atrial appendage occlusion in patients with atrial fibrillation and left appendage thrombus: feasibility, safety and clinical efficacy. EuroIntervention. 2018;13:1595\u2013602.","journal-title":"EuroIntervention"},{"key":"1335_CR66","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jacep.2019.11.017","volume":"6","author":"SP Sharma","year":"2020","unstructured":"Sharma SP, Cheng J, Turagam MK, Gopinathannair R, Horton R, Lam YY, et al. Feasibility of left atrial appendage occlusion in left atrial appendage thrombus: a systematic review. JACC Clin Electrophysiol. 2020;6:414\u201324.","journal-title":"JACC Clin Electrophysiol"},{"key":"1335_CR67","first-page":"263","volume":"7","author":"C-H Heeger","year":"2018","unstructured":"Heeger C-H, Metzner A, Schl\u00fcter M, et al. Cerebral protection during catheter ablation of ventricular tachycardia in patients with ischemic heart disease. J Am Heart Assoc. 2018;7:263.","journal-title":"J Am Heart Assoc"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-020-01335-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-020-01335-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:28:01Z","timestamp":1625876881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-020-01335-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1007\/s11886-020-01335-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"type":"print","value":"1523-3782"},{"type":"electronic","value":"1534-3170"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"10 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Stephan Haussig reports no conflict of interest.Axel Linke reports grants from Novartis; and personal fees from Medtronic, Abbott, Edwards Lifesciences, Boston Scientific, Astra Zeneca, Novartis, Pfizer, Abiomed, Bayer, and Boehringer; and stock options from Picardia, Transverse Medical, and Claret Medical.Norman Mangner reports personal fees from Edwards LifeSciences, Medtronic, Biotronik, Novartis, Sanofi Genzyme, and AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"96"}}